Today, we announced positive results from the landmark SOL-1 Phase 3 superiority trial in wet AMD, an important step forward as we aim to reduce the treatment burden, with the data presentation taking place at Macula Society this month. Learn more: ow.ly/svKn50YgYXM

What does meaningful durability really mean in #WetAMD care? And what happens when treatment burden gets in the way? At @RetinaSociety's Annual Meeting, five retina specialists weighed in on the questions shaping care today.​ ​ #RetinaOnRecord #RetinaRedefined

A superiority trial is designed to establish that one investigational treatment demonstrates better outcomes than an established therapy. At @asrsdocs, @ArshadKhanani explained why superiority sets a high bar. ​ ​ Learn more: ocutx.com/pipeline/ #ASRS2026 #WetAMD #MedEd

Retina specialists discussed the importance of superiority data to understand how a potential treatment compares with current standard-of-care options for wet AMD at @asrsdocs ​ Learn more: ow.ly/sHg150Zvbvb​ #RetinaOnRecord #ASRS2026 #RetinaRedefined

Retina specialists shared how filing based on a single Phase 3 clinical trial may help new treatment options reach patients sooner at @asrsdocs. Insights like these highlight the importance of our work to advance innovation for patients.​ Learn more: ow.ly/i13Q50ZvbsS

At @asrsdocs retina specialists reflected on how reducing treatment frequency may not only ease the burden for patients with wet AMD but could also support improved adherence and long-term visual outcomes. ​ Learn more: ow.ly/IJ9H50Zvbkh ​ #RetinaOnRecord #ASRS2026

At @asrsdocs retina specialists discussed why demonstrating superiority in a clinical trial can help provide confidence when evaluating treatment approaches for wet age-related macular degeneration.​ Learn more: ow.ly/Go1X50Zvb3K​ #RetinaOnRecord #ASRS2026

Today we shared Q2 2026 earnings and new data on what durability could mean for people with wet AMD. We also remain on track for an AMD NDA submission in Q4 2026 following a positive FDA Type C meeting. ​ ​ Learn more: bit.ly/4w9a5gf ​ $OCUL #RetinaRedefined

Retina specialists discussed why retinal fluid is an important marker of disease activity in wet AMD at @asrsdocs, reinforcing how reducing fluid fluctuations may help improve long-term visual outcomes.​ Learn more: ow.ly/Xb0Y50ZtA8C​ #RetinaOnRecord #ASRS2026

Retina specialists highlighted the connection between sustained disease control, reduced treatment burden, and long-term outcomes for patients with wet AMD during @asrsdocs. ​ Learn more: ow.ly/WRa150ZtA7k​ #RetinaOnRecord #ASRS2026 #RetinaRedefined

At @asrsdocs, retina specialists emphasized why maintaining fluid stability between treatments is an important goal in wet AMD and how sustained disease control may help support better long-term outcomes.​ Learn more: investors.ocutx.com/scientif…​ #RetinaOnRecord #ASRS2026

Retina specialists at @asrsdocs discussed why sustained disease control and reduced treatment burden are important unmet needs in the future of wet age-related macular degeneration care. ​ Learn more: investors.ocutx.com/scientif… ​ #RetinaOnRecord #ASRS2026 #RetinaRedefined

At @asrsdocs, retina specialists shared how pulsatile dosing can potentially impact long-term visual outcomes for patients with wet age-related macular degeneration. ​ Learn more: investors.ocutx.com/scientif…​ #RetinaOnRecord #ASRS2026 #RetinaRedefined

We’re looking forward to participating in the @HCWCO Ophthalmology Conference, where our Executive Chairman, President, and CEO Pravin Dugel, MD will discuss our clinical programs in wet AMD and diabetic retinopathy. Learn more: ow.ly/Wo9x50ZqRhB

At @asrsdocs, leading retina specialists discussed our landmark SOL-1 Phase 3 superiority clinical trial in wet AMD, real-world treatment outcomes, long-term disease management, and the regulatory pathway ahead. Learn more: ow.ly/o4IB50ZqbS0 #ASRS2026 #RetinaRedefined

At @OISTWEETS, Peter K. Kaiser, MD shared updates on our regulatory path in wet AMD, and Pravin Dugel, MD moderated a panel discussion on regulatory risk in the drug development process. Learn more about our mission to redefine the retina experience: ow.ly/KZvB50Zo2pc

Join leading retina specialists for a dinner symposium at @asrsdocs at 6 PM ET on July 16. ​ They will explore how durability and sustained disease control have the potential to redefine the management of wet AMD.​ Register now: ocutx.com/scientific-symposi…

At @asrsdocs, leading retina specialists will present data from our landmark SOL-1 Phase 3 superiority clinical trial and real-world analyses evaluating durability and long-term outcomes in wet AMD. Visit us at booth 600 to learn more: ow.ly/UO1A50ZiFjc

Join us at @OISTWEETS, where Peter K. Kaiser, MD will highlight our regulatory pathway in wet AMD. Pravin Dugel, MD will also moderate a panel discussion about navigating regulatory risk in clinical development. ​ Learn more: ocutx.com​ #RetinaRedefined

This content discusses an investigational drug, OTX‑TKI (AXPAXLI™), currently in development. Its safety and efficacy have not been established, and it is not approved for marketing by the FDA or any other health authority.

Chief Medical Officer Nadia Waheed, MD shared the significance of the SOL-1 Phase 3 superiority clinical trial in wet AMD, highlighting what this data may mean as Ocular aims to redefine the retina experience.​ Watch the conversation: vimeo.com/1204338459/1252d76… ​ #RetinaOnRecord